If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Nicotine Inhaler Launched in Sweden SAN ANTONIO, Dec. 5, 1996 -- Advanced Therapeutic Products, Inc. (ATP) announced that Pharmacia & Upjohn, Inc., the world leader in nicotine replacement therapy, will launch their nicotine inhaler as an over-the-counter (OTC) product in Sweden in mid-December. Based on technology originally developed by ATP, the Swedish launch is the second in a series of worldwide product launches. The nicotine inhaler debuted in Denmark in September, and according to Pharmacia & Upjohn's Dec. 5 press release, the response from smokers has exceeded all forecasts. In the release, Pharmacia & Upjohn indicated their expectation that the nicotine inhaler will become a success in Sweden as well. In 1987, ATP sold their patented nicotine technology to what is now Pharmacia & Upjohn in exchange for future royalties. That technology is now the basis for the nicotine inhaler. ATP previously announced that Pharmacia & Upjohn filed for regulatory approval with the United States FDA in the Spring of 1996. Upon regulatory clearance, the product will be marketed in the United States as the Nicotrol Inhaler by McNeil Consumers Products Company of Johnson and Johnson. The release of nicotine is controlled by inhaling air through a mouthpiece that contains a cartridge loaded with a nicotine impregnated plug. The air becomes saturated with vaporized nicotine which is then absorbed mainly through the lining of the mouth. According to Pharmacia & Upjohn, the nicotine dose is sufficient to relieve a smoker's craving, but delivers only a third of what a normal cigarette contains. Six clinical trials involving 1,440 smokers have demonstrated that the nicotine inhaler is a safe and effective product in relieving withdrawal symptoms and helping smokers quit.
|
